Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

679
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
679
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

686
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
686
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

628
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
628
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

452
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
452
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

661
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
661
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

835
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
835

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined large and small airway obstruction is associated with increased exacerbation frequency and poorer symptom control in persistent asthma.

The journal of allergy and clinical immunology. In practice·2026
Same author

Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial.

EULAR rheumatology open·2026
Same author

Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

American journal of respiratory and critical care medicine·2026
Same author

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma.

Allergy·2026
Same author

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

The Lancet. Respiratory medicine·2026
Same author

Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES.

The journal of allergy and clinical immunology. Global·2026

Related Experiment Video

Updated: Oct 17, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

JAK inhibitors for asthma.

Steve N Georas1, Patrick Donohue2, Margaret Connolly1

  • 1Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY.

The Journal of Allergy and Clinical Immunology
|October 9, 2021
PubMed
Summary
This summary is machine-generated.

Janus kinase (JAK) inhibitors show promise for treating asthma by targeting airway inflammation. Early research suggests these drugs could offer a new anti-inflammatory therapy for asthma patients.

Keywords:
AsthmaJAK InhibitorJAK/STAT pathwayJanus kinasesevere asthma

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Related Experiment Videos

Last Updated: Oct 17, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Asthma is an inflammatory airway disease involving cytokines and growth factors that activate Janus kinases (JAKs).
  • The JAK/signal transducer and activator of transcription (STAT) pathway is crucial for cell growth and differentiation.
  • JAK inhibitors are approved for other inflammatory conditions like rheumatoid arthritis and atopic dermatitis.

Purpose of the Study:

  • To review the rationale for using JAK inhibitors in various asthma endotypes.
  • To examine preclinical and early clinical evidence for JAK inhibitors in asthma treatment.
  • To assess safety data from JAK inhibitor use in other diseases.

Main Methods:

  • Review of preclinical data from systemic and inhaled JAK inhibitors in animal models of asthma.
  • Analysis of early clinical trial data for JAK inhibitors in asthma.
  • Evaluation of safety profiles from JAK inhibitors used in non-asthma conditions.

Main Results:

  • Substantial preclinical data indicate JAK inhibition can reduce airway inflammation and hyperreactivity in asthma models.
  • JAK inhibitors have demonstrated clinical efficacy in other immune and inflammatory diseases.
  • Early clinical evidence suggests potential benefits for asthma treatment.

Conclusions:

  • JAK inhibitors represent a promising therapeutic strategy for managing asthma.
  • Targeting the JAK/STAT pathway offers a novel approach to asthma anti-inflammatory treatment.
  • Further clinical investigation is warranted to establish the role of JAK inhibitors in asthma care.